Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „inhibit“
Suchtreffer
Begriffe & Kennungen
Adcirca (previously Tadalafil Lilly) · 4.3 · The co-administration of phosphodiesterase type 5 (PDE5) inhibitors, including tadalafil, with guanylate cycla
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.3 · The co-administration of phosphodiesterase type 5 (PDE5) inhibitors, including tadalafil, with guanylate cycla
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.5 · Cytochrome P450 inhibitors
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.5 · Cytochrome P450 inhibitors
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.5 · Protease inhibitors (e.g. ritonavir) Ritonavir (200 mg twice daily), which is an inhibitor of CYP3A4, CYP2C9,
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.5 · Protease inhibitors (e.g. ritonavir) Ritonavir (200 mg twice daily), which is an inhibitor of CYP3A4, CYP2C9,
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.5 · Riociguat Preclinical studies showed an additive systemic blood pressure lowering effect when PDE5 inhibitors
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.5 · Riociguat Preclinical trials showed an additive systemic blood pressure lowering effect when PDE5 inhibitors w
Eintrag öffnenAdempas · 4.3 · - Co-administration with PDE5 inhibitors (such as sildenafil, tadalafil, vardenafil) (see sections 4.2 and 4.5
Eintrag öffnenAdempas · 4.3 · - Co-administration with PDE5 inhibitors (such as sildenafil, tadalafil, vardenafil) (see sections 4.2 and 4.5
Eintrag öffnenAdempas · 4.5 · 30 PDE5 inhibitors Preclinical studies in animal models showed additive systemic blood pressure lowering effec
Eintrag öffnenAdempas · 4.5 · 32 Riociguat and its main metabolite are not inhibitors or inducers of major CYP isoforms (including CYP 3A4)
Eintrag öffnenAdempas · 4.5 · 8 Concomitant use with strong multi pathway CYP and P-gp/BCRP inhibitors The concomitant use of riociguat with
Eintrag öffnenAdempas · 4.5 · Concomitant use with CYP1A1, UGT1A1 and UGT1A9 inhibitors From the recombinant CYP isoforms investigated in vi
Eintrag öffnenAdempas · 4.5 · Concomitant use with CYP1A1, UGT1A1 and UGT1A9 inhibitors From the recombinant CYP isoforms investigated in vi
Eintrag öffnenAdempas · 4.5 · Concomitant use with other CYP and P-gp/BCRP inhibitors Medicinal products strongly inhibiting P-gp/BCRP such
Eintrag öffnenAdempas · 4.5 · Concomitant use with other CYP and P-gp/BCRP inhibitors Medicinal products strongly inhibiting P-gp/BCRP such
Eintrag öffnenAdempas · 4.5 · Concomitant use with strong multi pathway CYP and P-gp/BCRP inhibitors The concomitant use of riociguat with s
Eintrag öffnenAdempas · 4.5 · PDE5 inhibitors Preclinical studies in animal models showed additive systemic blood pressure lowering effect w
Eintrag öffnenAdempas · 4.5 · Riociguat and its main metabolite are not inhibitors or inducers of major CYP isoforms (including CYP 3A4) or
Eintrag öffnen